Search

This article from Reactions Weekly describes a case report involving a male neonate who experienced a lack of efficacy while being treated with immunoglobulin-G for cholangitis. The neonate was born prematurely and had autosomal recessive polycystic kidney disease. He underwent various medical procedures and developed complications such as peritoneal leakage, fungal peritonitis, catheter-related bloodstream infection, and sepsis. Despite receiving immunoglobulin-G, the neonate developed sepsis secondary to his cholangitis, indicating that the treatment was not effective. He also had severe pulmonary hypoplasia. [Extracted from the article]

A 31-year-old man with autosomal recessive polycystic kidney disease and caroli disease experienced lack of efficacy during treatment with vitamin-D and cinacalcet for secondary hyperparathyroidism. Despite receiving vitamin-D therapy, his intact PTH levels continued to increase, indicating lack of efficacy. Cinacalcet treatment also did not provide any benefit. He later developed severe anemia and was treated with etelcalcetide, which gradually reduced his intact PTH levels and improved his clinical condition. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series, 3 women age: 20-48 years were described, who developed acute liver allograft rejection following administration of the tozinameran COVID-19 vaccine. Three years after the transplant, she received the first dose of the tozinameran vaccine [Pfizer-BioNTech vaccine]. [Extracted from the article]

Eight of these patients were additionally receiving peritoneal dialysis (4 patients) and haemodialysis (4 patients). Subsequently, the hypertension resolved in one patient and persisted in one patient requiring continuation of antihypertensive therapy. Subsequently, hypertension resolved in all the nine patients, and the patients remained off anti-hypertensive medication [ I outcome not stated i ]. [Extracted from the article]

Additionally, he exhibited lack of efficacy during treatment with furosemide, for oliguria and prednisolone and methylprednisolone for cellular graft rejection. During second transplant, he received induction immunosuppressant therapy with basiliximab, and started receiving maintenance immunosuppression with tacrolimus, mycophenolate mofetil and prednisolone. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 17-year old boy developed acute respiratory distress syndrome (ARDS) during treatment with alemtuzumab for cellular graft rejection. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a single-center, retrospective analysis of 5 patients, who underwent kidney transplantation (KTx) and received valganciclovir prophylaxis for cytomegalovirus (CMV) infection between August 2018 and March 2019 at the Tokyo Women's Medical University, Japan, 4 male patients aged 11-19 years were described, who developed neutropenia, anaemia, poor appetite or diarrhoea during treatment with valganciclovir for CMV infection prophylaxis [ I frequencies and durations of treatments to reactions onsets not stated i ]. The patients, who had cystic kidney disease, autosomal recessive polycystic kidney disease (ARPKD), bilateral renal hypoplasia, or primary focal segmental glomerulosclerosis (FSGS), underwent living donor kidney transplantation under immunosuppressant therapy without any complications. However, the patients developed neutropenia (1 patient), anaemia (2 patients), and neutropenia with poor appetite and diarrhoea (1 patient). [Extracted from the article]

Following renal transplantation, six out of the 11 patients were placed on induction immunosuppressive therapy comprising basiliximab (3 patients) and daclizumab (3 patients) and the remaining 5 patients did not receive any induction immunosuppressive therapy. Three out of the 11 patients were also found to have BK viraemia associated nephropathy 45-379 days after the diagnosis of BK viraemia. [Extracted from the article]